Physician profile
William David Smith
NPI 1174579429
$4,034.91
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $516 · 2021: $1,152 · 2022: $1,256 · 2023: $242 · 2024: $68.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $503.90 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Novo Nordisk INC | $489.68 | 2019-2022 | |
| Lilly USA, LLC | $405.08 | 2019-2022 | |
| Abbvie INC. | $404.75 | 2021-2022 | |
| Amgen INC. | $384.55 | 2019-2023 | Evenity, Prolia |
| Pfizer INC. | $339.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $176.24 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $172.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $119.37 | 2019-2022 | |
| Grifols USA, LLC | $101.53 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $77.56 | 2019-2021 | |
| Esperion Therapeutics, INC. | $70.03 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $68.93 | 2022-2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $58.89 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $54.00 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.76 | 2021-2022 | |
| Amarin Pharma, INC. | $49.46 | 2020-2021 | |
| Allergan, INC. | $47.35 | 2020 | |
| Sanofi-Aventis U.S. LLC | $43.96 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.48 | 2022 | |
| Edwards Lifesciences Corporation | $36.90 | 2020-2021 | |
| Radius Health, INC. | $34.12 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.90 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.72 | 2020 | |
| Amryt Pharma Holdings Ltd | $15.32 | 2021 | |
| Boston Scientific Corporation | $14.04 | 2019 | |
| Genentech USA, INC. | $13.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.33 | 2021 | |
| Hikma Pharmaceuticals USA | $11.70 | 2021 | |
| Eyevance Pharmaceuticals LLC | $11.70 | 2021 | |
| Shire North American Group INC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.